Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425292 · ClinicalTrials.gov registry record · Phase 1
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
A Phase 1 study, sponsored by Saint John's Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03425292 is a Phase 1 study that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 49 participants.
The verdict
NCT03425292, a Phase 1 study, has completed, sponsored by Saint John's Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma. Additional aims of the study are to: * Find out side effects (good and bad) of study drug combinations. * Evaluate any preliminary evidence of anticancer activity of study drug combinations . * Evaluate tumor characteristics by collecting brain tumor tissue samples. * Measure the amount of nivolumab and ipilimumab in biospecimens. * Look at biomarkers in biospecimens.
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Temozolomide
- RADIATION conformal brain radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425292
The ClinicalTrials.gov registry entry for NCT03425292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03425292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03425292 about?
NCT03425292 is a clinical study titled "A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer". The purpose of this study is to test the safety and tolerability of the research study drugs nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery and before standard therapy with radiation and temozolomide in patients with newly diagnosed high grade glioma. Ad...
What is the current status of trial NCT03425292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-03-01. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT03425292?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Temozolomide (DRUG), conformal brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03425292?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.